Nanotechnology drug delivery market to touch $11.9 billion in 2023
Rising prevalence of infectious diseases and cancer, significant nanotechnology research, and increasing demand for novel drug delivery systems are driving the nanotechnology market.
Transparency Market Research has published a new market research report titled, "Nanotechnology Drug Delivery Market — Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015–2023." According to the report, the global nanotechnology drug delivery market was valued at $4.1 billion in 2014 and is estimated to reach $11.9 billion in 2023, expanding at a CAGR of 12.5% from 2015 to 2023.
Application of nanotechnology is aimed at improving drug delivery. Advancement in nanotechnology has revolutionized the delivery of nanometer range of drug molecules. Rising prevalence of infectious diseases and cancer, significant nanotechnology research, and increasing demand for novel drug delivery systems are driving the nanotechnology market. However, unspecific regulatory guidelines for novel nanotechnology-based drugs is expected to hamper market growth during the forecast period. The global nanotechnology drug delivery market was valued at $4.1 billion in 2014 and is anticipated to reach $11.9 billion by 2023, expanding at a CAGR of 12.5% from 2015 to 2023.
Nanoparticles dominated the global nanotechnology drug delivery market in 2014 due to wide range of applications and increase in demand for nanoparticles globally. The dendrimers sub-segment dominated the nanoparticles segment owing to factors such as polyvalency, flexibility in size and shape, monodispersity, biocompatibility, and better transfection properties than other technologies. However, the nanotubes segment is expected to expand at the highest growth rate during the forecast period. Growth of this segment is attributed to high efficiency of nanotubes in health care specifically in drug delivery, bio-sensing methods for disease treatment, and health monitoring.
Oncology was the largest application segment of the nanotechnology drug delivery market in terms of revenue in 2014. The segment is expected to dominate the market during the forecast period. Rise in demand for effective treatment therapies for cancer coupled with increasing incidence of this disease drives the oncology application segment. Neurology was the second largest application segment of the nanotechnology drug delivery market in 2014 due to efficient application of nanotechnology in neuromolecular diagnostics and discovery of neurodegenerative markers.
The cardiovascular application segment is expected to expand at the highest CAGR during the forecast period from 2015 to 2023. Most of the research studies related to nanotechnology-based cardiovascular treatment drugs are in pipeline; however, groundbreaking innovation in this field is expected to drive this market.
The global nanotechnology drug delivery market is consolidated, with relatively small number of companies accounting for majority of the market share in 2014. AbbVie, Amgen, Johnson & Johnson, Novartis and Teva Pharmaceutical Industries are the key players in the global nanotechnology drug delivery market.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance